Dr. Marc Ouellette is an investigator at the Infectious Diseases and Immunity Axis of the Research Centre of the CHU de Québec-Laval University. He is also a full professor at the Department of Microbiology-Infectious Diseases and Immunology at the Laval University School of Medicine. His work focuses on antimicrobial resistance. Dr. Ouellette holds a Canada Research Chair in antimicrobial resistance and was the Scientific Director of the CIHR Institute of Infection and Immunity from 2010-2018. He is a fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences.

Dr. Ouelette’s work focuses on the protozoan parasite Leishmania and on different bacteria, including the pneumococcus. Leishmania is a neglected tropical disease that affects over 12 million people, while antibiotic resistance is a major public health issue that is receiving unprecedented political attention. His team uses several screens coupled to next-generation sequencing to find novel biomarkers of resistance in parasites and bacteria. Their screens are also used to identify new drug cellular targets against new molecules or also to define death and survival pathways that could be exploited for novel therapeutic strategies.

CHUL
2705, boulevard Laurier
R-0709
Québec, Québec
Canada G1V 4G2
209 entries « 1 of 21 »

Van den Kerkhof M, Leprohon P, Mabille D, Hendrickx S, Tulloch LB, Wall RJ, Wyllie S, Chatelain E, Mowbray CE, Braillard S, Ouellette M, Maes L, Caljon G

Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series.

Journal Article

Microorganisms, 9 (7), 2021.

Abstract | Links:

Morelle C, Mukherjee A, Zhang J, Fani F, Khandelwal A, Gingras H, Trottier J, Barbier O, Leprohon P, Burke MD, Ouellette M

Well-Tolerated Amphotericin B Derivatives That Effectively Treat Visceral Leishmaniasis.

Journal Article

ACS Infect Dis, 7 (8), 2021.

Abstract | Links:

Bhattacharya A, Leprohon P, Ouellette M

Combined gene deletion of dihydrofolate reductase-thymidylate synthase and pteridine reductase in Leishmania infantum.

Journal Article

PLoS Negl Trop Dis, 15 (4), 2021.

Abstract | Links:

Potvin JE, Leprohon P, Queffeulou M, Sundar S, Ouellette M

Mutations in an Aquaglyceroporin as a Proven Marker of Antimony Clinical Resistance in the Parasite Leishmania donovani.

Journal Article

Clin Infect Dis, 72 (10), 2021.

Abstract | Links:

Bhattacharya A, Bigot S, Padmanabhan PK, Mukherjee A, Coelho A, Leprohon P, Papadopoulou B, Ouellette M

New insights in the mode of action of anti-leishmanial drugs by using chemical mutagenesis screens coupled to next-generation sequencing.

Journal Article

Microb Cell, 7 (2), 2020.

Abstract | Links:

Gingras H, Patron K, Leprohon P, Ouellette M

Azithromycin resistance mutations in as revealed by a chemogenomic screen.

Journal Article

Microb Genom, 6 (11), 2020.

Abstract | Links:

Douanne N, Wagner V, Roy G, Leprohon P, Ouellette M, Fernandez-Prada C

MRPA-independent mechanisms of antimony resistance in Leishmania infantum.

Journal Article

Int J Parasitol Drugs Drug Resist, 13 , 2020.

Abstract | Links:

Ouellette M, Bhattacharya A

Exploiting antimicrobial resistance: Better knowledge of resistance mechanisms can inform the search for and development of new antibiotics.

Journal Article

EMBO Rep, 21 (4), 2020.

Abstract | Links:

Van den Kerkhof M, Mabille D, Hendrickx S, Leprohon P, Mowbray CE, Braillard S, Ouellette M, Maes L, Caljon G

Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance.

Journal Article

Antimicrob Agents Chemother, 64 (9), 2020.

Abstract | Links:

El Khoury JY, Maure A, Gingras H, Leprohon P, Ouellette M

Chemogenomic Screen for Imipenem Resistance in Gram-Negative Bacteria.

Journal Article

mSystems, 4 (6), 2019.

Abstract | Links:

209 entries « 1 of 21 »
Signaler des ajouts ou des modifications

Active projects

  • Chaire de recherche du Canada sur la résistance aux antiantimicrobiens, from 2017-04-01 to 2024-03-31
  • Drug resistance and drug targets in the protozoan parasite Leishmania, from 2019-10-01 to 2024-09-30
  • Genomics of antimicrobial resistance and drug/target discovery, from 2019-07-01 to 2027-06-30
  • Les bactériocines : une alternative naturelle fort prometteuse pour le remplacement des antibiotiques en production avicole., from 2019-04-01 to 2023-06-30
  • MAchine learning for diGItal diagnosTICS of antimicrobial resistance, from 2019-10-01 to 2022-09-30

Recently finished projects

  • Canada Research Chair in Medical genomics, from 2018-08-01 to 2019-12-31
  • Centre de recherche sur les interactions hôte-parasite (CRIHP), from 2015-04-01 to 2021-03-31
Data provided by the Université Laval research projects registery